Plain-English translation of NCT05260957 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination treatment for aggressive non-Hodgkin's lymphoma that has either come back after treatment or didn't respond to chemotherapy the first time. The combination includes (where your own immune cells are trained to fight cancer) followed by two antibody medications: and vedotin. Researchers want to see if this three-part approach can shrink the lymphoma in patients who have limited other options.
Aggressive lymphomas that don't respond to standard chemotherapy or come back after treatment are very difficult to cure. This trial is exploring whether combining newer approaches—using your body's own immune system plus targeted antibody drugs—might work better than current options for patients in this difficult situation.
You likely qualify if…
You likely don't qualify if…
You would receive treatment across three phases over roughly 4 months. First, you'll receive two antibody medications weekly for about 6 weeks before the main treatment. Then you'll come in for 3 days of chemotherapy to prepare your immune system, followed by a single infusion of your CAR-T cells. Finally, over the next 3 months, you'll return to clinic for additional doses of the antibody medications. You'll have regular clinic visits, blood tests, and imaging scans to monitor how well the treatment is working and to watch for side effects.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States